LifeMD shares plummeted over 28% to $8.48 after the telemedicine company reported dismal Q2 2025 results, missing both revenue and earnings forecasts. The firm posted a loss of $0.06 per share—triple analysts’ expectations—while revenue of $62.2 million fell $4 million short. Compounding investor anxiety, management slashed its full-year revenue guidance to $250–255 million, down from $268–275 million. The RexMD men’s health division struggled with soaring customer acquisition costs and declining conversion rates, overshadowing growth in weight management, where 400+ daily sign-ups were marred by rising refund demands due to unaffordable branded drug costs.
Insider Moves and Structural Challenges
Despite CEO stock sales worth $250,000, LifeMD maintains ambitious 2025 targets, including $200 million from telemedicine and $55 million from WorkSimpli. While debt-free with $36.2 million cash, operational hurdles—particularly RexMD’s underperformance and pricing pressure from cheaper competitors—have eroded confidence. Analysts question whether the company can reconcile its optimistic projections with persistent execution risks.
Ad
LifeMD Stock: Buy or Sell?! New LifeMD Analysis from December 22 delivers the answer:
The latest LifeMD figures speak for themselves: Urgent action needed for LifeMD investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 22.
LifeMD: Buy or sell? Read more here...
